Objectives. To investigate the prevalence of diabetes in patients with RA and the impact of diabetes on self-reported outcomes and health care.
Introduction
RA is associated with an increased incidence and prevalence of diabetes [1, 2] . Furthermore, the risk of undiagnosed diabetes is elevated in patients with RA, especially in those with long-standing disease [3] . Adjusted comparisons with the general population indicate that the higher incidence is mainly driven by obesity, lifestyle factors and comorbidity [4] . Certain DMARDs, including TNF-a inhibitors, seem to decrease the incidence of diabetes in patients with RA by improving the markers of glucose metabolism [57] , while glucocorticoids and statins are likely associated with an increased risk [8] . The coexistence of RA and diabetes increases cardiovascular risk [9] . These facts indicate that high diabetes prevalence and the resulting complications in patients with RA may be reduced by increasing awareness of the risk factors for diabetes at the patient level and by providing adequate anti-inflammatory RA therapy at the health care level.
To assess the impact of diabetes in patients with RA, reliable data on diabetes prevalence and RA-related outcomes are required. RA cohorts cover data on disease activity and socioeconomic factors, whereas diabetes, as a comorbid condition, is reported either by the rheumatologist or the patient [1012] . Furthermore, RA cohorts mostly represent RA patients in rheumatological care. In health care databases, diabetes is assessed by diagnostic codes and specific medications, whereas data on RA disease activity are missing [1, 2, 4, 5]. We took advantage of claims data linked to self-reported patient outcomes from a questionnaire survey within the network Linking PatientReported Outcomes with CLAIms data for health services research in Rheumatology (PROCLAIR) [13] . This linkage enables an investigation of the prevalence of diabetes in patients with RA by socioeconomic factors in a population-based setting and enables the assessment of the impact of diabetes on self-reported RA outcomes and the health care status of these patients.
Methods
This study was conducted using a cross-sectional design. Using data from a nationwide statutory health insurance fund (BARMER), RA patients between the age of 18 and 79 years were identified based on a diagnostic code of RA (M05, M06), according to the German modification of the International Statistical Classification of Diseases (ICD-10-GM) in at least two quarters of 2013 [13] . In 2015, an age, sex and diagnosis (M05 and M06) stratified random sample of 6600 people was provided with a questionnaire covering RA diagnosis confirmation, access to rheumatological care, self-reported disease burden, lifestyle factors and RA impacts on social and working life [14] . Patients gave their written informed consent for the linking of information derived from the questionnaire to claims data. Ethical approval was obtained from the ethics committee of the Charité University Medicine in March of 2015 (EA1/ 051/15). This research was conducted in agreement with the Declaration of Helsinki. The study was performed within the research networks PROCLAIR and Metabolic Impact on Joint and Bone Diseases (METARTHROS) [14, 15] .
Claims data
Age, sex, postal code, insurance status and comorbidities were assessed in the claims data from 2015. We identified patients with diabetes mellitus who were coded with the diagnoses E10E14 in outpatient care in at least two quarters of 2015. Additional cardiovascular, respiratory and other comorbidities were also assessed with the data from 2015, and at least one diagnosis had to be documented in outpatient care (ICD-10 codes are reported in Table 2 ). Drug prescriptions in 2015 were identified via the anatomical therapeutic chemical classification as follows: conventional synthetic DMARDs (L04AA13, L04AD01, L04AX01, L04AX03, M01C), biologics (L04AA24, L04AB, L04AC03, L04AC07, L01XC02), glucocorticoids (H02AB, H02BX), NSAIDs (M01A), oral antidiabetics (A10B), insulin (A10A), anti-hypertensive agents (C02, C08, C09), diuretics (C03), statins (C10AA), anti-depressants (N06A) and analgesics were assessed according to a previously used reference list of anatomical therapeutic chemical codes [16] .
Questionnaire data RA diagnosis confirmation (what is your disease called by the physician?), disease duration and rheumatological care (current/ever) were covered in the questionnaire. Tender and swollen joints were assessed by 50 and 48 joint counts for tenderness and swelling in a patient-reported question/mannequin format [17, 18] . Disability was assessed by the physical Functional Questionnaire Hannover (FFbH, range 0100: full functional capacity) [19] . The impact of RA disease was ascertained by the RA Impact of Disease score (RAID; range 0: no impact, to 10: highest impact) [20, 21] . The WHO's Five-item Wellbeing Index (WHO-5; scores transformed to 0100) was used to determine the depressive symptoms based on the last 2 weeks. The depressive symptoms were categorized as mild (2950) or moderate to severe (028), whereas patients scoring above 50 were considered to have no depressive symptoms [16] . BMI (kg/m 2 ), household income (<1500, 15003200 and >3200 E), smoking (current, ever), lack of exercise and changes in dietary habits were ascertained as socioeconomic and lifestyle variables. As education status is highly associated with household income, income was used as a proxy for socioeconomic status [14] .
Statistical analysis
The total number of people who returned the questionnaires was weighted according to the age, sex and diagnosis distribution (M05 or M06) of the source population. People with RA who confirmed their RA diagnosis were classified as having diabetes or not. Descriptive statistics [mean, standard error of the mean (S.E.M.), percentages] were used to compare persons with RA with or without diabetes. The S.E.M. is used instead of the S.D. due to the stratified nature of the study sample. To account for differences between both groups, the results of those without diabetes are reported unweighted and weighted according to the age, sex and diagnosis (M05 and M06) distribution of the patients with diabetes. The prevalence of diabetes in people with RA was analysed by age, sex, region of residence, household income and BMI. All analyses were conducted using procedures for complex survey designs performed with SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA). The RaoScott chi-square test was used to study differences between RA patients with and without diabetes, and the weighted results were compared. A multivariate regression analysis was performed with PROC SURVEYLOGISTIC to study the influence of diabetes on being in rheumatological care, adjusting for age group (1849, 5064 and 6579 years), sex (male and female), BMI (<25.0, 25.0 to < 30 and 530.0 kg/m 2 ), diagnosis (M05 and M06), household income (<1500, 15003200 and >3200 E), tobacco use (current/former and never) and functional status (FFbH; <50, 5070 and >70100).
Results

Patient characteristics
From a total of 6600 randomly selected people with an RA diagnosis, 6193 patients were still insured in 2015 and received the questionnaire. Of those patients, a total of 3184 people responded, and 3140 gave their consent for linking the questionnaire data to claims data (51%). A total of 2535 people confirmed the RA diagnosis (80%). Of the 2535 people with confirmed RA, 498 (19.7%) had at least two diabetes diagnostic codes. In addition, 65% of people with RA and diabetes diagnosis received at least one prescription of oral antidiabetics (45%) and/or insulin (27%). Furthermore, the mean disease duration was comparably long (16 years), and people with RA and diabetes were, on average, 6.6 years older, more often male (28.8% vs 18.3%) and more often obese (34.7% vs 16.9%) than people with RA without diabetes. People with RA and diabetes were more frequently former smokers but were less often current smokers. They reported a lack of exercise significantly more often, reported less frequent diet changes and had a higher BMI (Table 1) . To account for the age and sex differences between groups, self-reported outcomes, further comorbidities and drug prescriptions were compared using the weighted results. To consider differences in obesity, self-reported outcomes were reported by BMI categories.
Diabetes prevalence in RA Diabetes was more frequent in males, in older patients, in patients with a higher BMI and in patients with a lower socioeconomic status (Fig. 1) . The prevalence of diabetes was slightly higher in males who use tobacco and was higher in the Eastern federal states of Germany that belonged to the German Democratic Republic until 1990. Prevalence and confidence intervals are reported in the Supplementary Appendix Table S1 , available at Rheumatology Online.
Self-reported RA outcomes
Compared with patients without diabetes, patients with RA and diabetes had, on average, 1.2 more swollen and (Fig. 2 ).
Comorbidity and drug prescriptions in RA patients with or without diabetes
Patients with RA and diabetes more frequently had cardiovascular diseases (35% vs 15%), depression (39% vs 26%), renal failure (23% vs 8%), polyneuropathy (20% vs 0.8%), retinopathy (12% vs 0.8%, all P < 0.0001) and venous ulcer (5% vs 1.9%, P < 0.05). These differences remained when adjusting for BMI values. Compared with patients without diabetes, patients with RA and diabetes were treated more frequently with antihypertensive drugs (74% vs 50%), statins (37% vs 23%), diuretics (30% vs 17%) and antidepressants (30% vs 15%, all P < 0.0001) ( Table 2) .
Rheumatological care for people with RA and diabetes
Patients with RA and diabetes were less frequently under rheumatological care (57% vs 67%, P = 0.004) than those without diabetes. A total of 42% of the patients with diabetes (vs 33% without, P = 0.019) were hospitalized at least once in 2015. The mean duration of the hospital stay was, on average, 2 days longer than that of the patients without diabetes [15.2 (15.6) vs 13.4 (19.4)]. The patients with RA and diabetes less frequently received DMARDs (40% vs 48%, P = 0.034). Glucocorticoids (48% vs 51%), NSAIDs (44% vs 45%) and analgesics (78% vs 69%) were frequently prescribed, despite these patients having diabetes. There was no difference in the prescription of biologics (12% vs 13%, P = 0.64).
In the univariate and multivariate regression analyses, the M05 diagnosis, a younger age and not having diabetes were associated with a higher chance of being treated by a rheumatologist. There was no association for socioeconomic factors and functional status (Table 3) .
Discussion
In this population-based sample of people with RA, onefifth had concomitant diabetes. Considering the sex-and age-specific estimates, the prevalence of diabetes diagnosis was 1015% higher than that in the general German population, reported from a recent study using data of all German health insurance funds [22] . A previous age-and sex-matched comparison with non-RA patients confirmed a higher prevalence of diagnosed diabetes in 20.8% of patients with RA compared with 17% of patients without RA [23] . The global prevalence of diabetes among RA patients ranges between 6 and 14% [11, 24, 25] . The high rate in the present study is partly explained by the high average age of the sample. Analogous to the general German population, the prevalence of diabetes was higher in males, in those with a higher BMI, in those with a lower socioeconomic status and in those located in the former East Germany [26] . For diabetes in general, these regional differences can be explained by socioeconomic   FIG. 1 Diabetes prevalence in patients with RA Diabetes prevalence was analysed by sex, age, BMI, region of residence and household income. and environmental factors, as well as regional deprivation [27] . We found a very similar regional pattern in patients with RA. However, male sex and obesity had the highest impact. Obesity was also responsible for the apparently higher disease burden in patients with RA and diabetes. These differences disappeared once the results were viewed within the different BMI categories. This observation is comparable to data from a cohort study by Dubreuil et al. [4] in which a substantial part of the increased incidence rates of diabetes in RA patients were attributed to BMI, smoking and alcohol. Part of the worse outcome measures in patients with RA and diabetes may not be related to diabetes, but may account for persons with diabetes generally being in poorer health. This was confirmed by the high prevalence of comorbidities in patients with RA and diabetes, including cardiovascular disease, depression, renal failure, polyneuropathy and retinopathy. Type 2 diabetes increases cardiovascular risk in patients with RA [9] . The impact of diabetes in patients with RA on non-cardiovascular comorbidities is less often investigated. However, these comorbid conditions are also of concern because they complicate RA management. We found a high prevalence of depression in people with RA and diabetes. The reported prevalence of depression ranges from 7 to 33% in people with type 2 diabetes compared with 419% in people without diabetes [28] . In longitudinal data from general practices in Germany, 30% of people with diabetes had a diagnosis of depression within 10 years [29] , and 22% of people with RA had a diagnosis of depression within 5 years [30] . In people with RA, depression is reported in 1539% of patients, depending on the definition and age of the sample [31] . Thus, depression is highly prevalent in patients with both diseases.
It was expected and confirmed by the present data that people with RA and diabetes are more frequently hospitalized than people without diabetes. However, it was surprising that only 57% of these people reported being under current rheumatological care. Possible reasons for insufficient specialty care include other specialty health FIG. 2 Self-reported outcomes in patients with RA with or without diabetes Self-reported swollen joint counts (SJC, 048), tender joint counts (TJC, 050), RA Impact of Disease score (RAID; 010) and WHO's Five-item Well-being Index (WHO-5; 0100) are distributed by BMI category for people with RA and diabetes compared with those without diabetes. All results are weighted for age and sex differences.
care, for example, general internal or diabetes care, a higher tendency to avoid medical care (compliance), other comorbid conditions given priority or the substantial immobility of patients with diabetes. However, our data did not show that any of these factors were associated with a lack of rheumatological care. Therefore, reasons for the lack of specialty health care in this risk group require further investigation.
Treatment with DMARDs is essential for patients with RA and in those who also have diabetes; it is even more important that they avoid treatment with glucocorticoids. Our observation that about half the patients with RA and diabetes received glucocorticoids and NSAIDs and threequarters received analgesics but only 41% received DMARDs needs further attention since it may reflect suboptimal treatment strategies.
Limitations
This study is based on claims data; therefore, the diagnoses of RA and diabetes could not be confirmed by external clinical validation. We addressed this problem by using self-reported validation of RA diagnosis as an inclusion criterion and by reporting the proportions of patients under current diabetes therapy instead. To limit the risk of overestimation, at least two diagnostic codes in two quarters were required. The comparison with the general population within the claims data is not influenced by overestimation [23] . Uncertainty remains regarding undiagnosed diabetes that cannot be estimated without clinical examination.
The main strength of the study is the linkage of the claims data to the survey results, enabling confirmation of RA diagnosis by patient reports and controlling for BMI, sociodemographic and lifestyle factors.
In summary, the health care of people with RA and diabetes is important on the individual level, and the socioeconomic level because these people represent a risk group for high disease burden, morbidity and hospitalization. Reasons for insufficient specialized care need to be further explored. Obesity increases the disease burden of patients with RA and diabetes and should be considered for both preventing diabetes and improving RA outcomes. 
